Published in Drug Des Devel Ther on April 01, 2015
Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs (2015) 0.83
Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab (2015) 0.82
Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs. PLoS One (2016) 0.78
Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab (2016) 0.77
Activity of daily living for Morquio A syndrome. Mol Genet Metab (2016) 0.76
Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine. Protein Cell (2015) 0.76
Current therapies for Morquio A syndrome and their clinical outcomes. Expert Opin Orphan Drugs (2016) 0.75
Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris. Sci Rep (2016) 0.75
Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs. Mol Genet Metab (2015) 0.75
Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels. Mol Genet Metab Rep (2017) 0.75
Diagnosis of Morquio-A patients in Mexico: How far are we from prompt diagnosis? Intractable Rare Dis Res (2017) 0.75
Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med (2001) 4.28
Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med (2004) 4.15
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med (2006) 4.04
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr (2007) 3.40
Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med (2012) 3.27
Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res (2008) 2.64
Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv (2009) 2.26
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis (2007) 2.21
The nature and significance of osteopontin. Connect Tissue Res (1989) 2.04
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab (2008) 2.04
Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol (2004) 2.04
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr (2004) 1.94
The primary structure of a cell-binding bone sialoprotein. J Biol Chem (1988) 1.93
Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr (1998) 1.91
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood (2013) 1.91
Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest (1993) 1.81
Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol (2011) 1.78
Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest (2008) 1.70
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet (2006) 1.65
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl (2002) 1.63
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab (2013) 1.57
A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess (2006) 1.56
Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr (2013) 1.51
Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant (2003) 1.50
Treatment of lysosomal storage disorders : progress with enzyme replacement therapy. Drugs (2007) 1.47
Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Blood (2014) 1.46
Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med (1984) 1.43
Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant (2007) 1.42
Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol (2001) 1.38
Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop (2003) 1.37
Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet (2012) 1.37
Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis (2012) 1.32
Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet (2007) 1.32
Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab (2012) 1.30
Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis (1999) 1.27
Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab (2013) 1.26
Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br (1994) 1.26
Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25
Transplant outcomes in mucopolysaccharidoses. Semin Hematol (2010) 1.25
Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet (2006) 1.24
Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis (2009) 1.22
The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes. Gene (2003) 1.20
Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child (1997) 1.20
Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr (2009) 1.19
Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis (2011) 1.17
Hematopoietic cell therapy for metabolic disease. J Pediatr (2007) 1.17
Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet (2001) 1.17
Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res (2004) 1.16
Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop (1997) 1.15
The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr Neurol (2003) 1.13
Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab (2013) 1.13
Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology (2001) 1.12
Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth (2012) 1.11
Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab (2006) 1.10
Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res (2000) 1.10
Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther (2010) 1.10
Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis (2010) 1.09
Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Disord (2012) 1.08
Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet (2003) 1.08
Growth charts for patients with Hunter syndrome. Mol Genet Metab Rep (2014) 1.08
Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One (2010) 1.06
Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis (2006) 1.06
Heterogeneity of Morquio disease. Clin Genet (1986) 1.05
The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr (1995) 1.05
Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab (2014) 1.04
Mobility in Hurler syndrome. J Pediatr Orthop (2008) 1.04
Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr (2007) 1.03
Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant (1998) 1.02
Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab (2013) 1.02
Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases. J Clin Invest (1992) 1.01
Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab (2014) 0.99
Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood (2001) 0.98
Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab (2007) 0.97
Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta Paediatr (2009) 0.97
Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark Insights (2011) 0.96
A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes. Nat Biotechnol (2012) 0.96
Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab (2008) 0.94
Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis (1999) 0.94
Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. JIMD Rep (2014) 0.93
A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis (2013) 0.91
Research priorities in biomarkers and surrogate end-points. Br J Clin Pharmacol (2012) 0.91
Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant (2007) 0.91
Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab (2012) 0.91
Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target (2001) 0.91
Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab (2010) 0.91
Fetal presentation of Morquio disease type A. Prenat Diagn (1992) 0.90
Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab (2014) 0.89
Skeletal dysplasias: evaluation with impulse oscillometry and thoracoabdominal motion analysis. Pediatr Pulmonol (2010) 0.89
First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta (2012) 0.89
The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant (2008) 0.89
Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep (2015) 0.88
Prevalence and development of orthopaedic symptoms in the dutch hurler patient population after haematopoietic stem cell transplantation. JIMD Rep (2012) 0.86
Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Pediatr Transplant (2013) 0.86
Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World J Pediatr (2008) 0.85
Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev (2014) 0.85
Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Disord (2012) 1.08
Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab (2014) 0.89
Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep (2015) 0.88
Detailed analysis of 26 cases of 1q partial duplication/triplication syndrome. Am J Med Genet A (2016) 0.86
Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses. Mol Genet Metab (2014) 0.86
Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech (2014) 0.86
Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs (2015) 0.83
Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab (2015) 0.82
Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements. Mol Genet Metab Rep (2015) 0.79
Obstructive airway in Morquio A syndrome, the past, the present and the future. Mol Genet Metab (2015) 0.79
Human recombinant lysosomal enzymes produced in microorganisms. Mol Genet Metab (2015) 0.79
Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica (2015) 0.79
Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine. Haematologica (2015) 0.77
Glycosaminoglycans detection methods: Applications of mass spectrometry. Mol Genet Metab (2016) 0.77
Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab (2016) 0.77
The phenotype and clinical course of Japanese Fanconi Anaemia infants is influenced by patient, but not maternal ALDH2 genotype. Br J Haematol (2016) 0.77
Activity of daily living for Morquio A syndrome. Mol Genet Metab (2016) 0.76
Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukuriningu Gakkai Shi (2015) 0.76
Current therapies for Morquio A syndrome and their clinical outcomes. Expert Opin Orphan Drugs (2016) 0.75
Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris. Sci Rep (2016) 0.75
Non-invasive pulmonary function test on Morquio patients. Mol Genet Metab (2015) 0.75
Sequential strategy for umbilical cord blood transplantation in a Korean Fanconi anemia girl with refractory acute myelomonocytic leukemia and complex karyotype. Pediatr Transplant (2016) 0.75
Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatr Blood Cancer (2019) 0.75
Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biol Blood Marrow Transplant (2017) 0.75
Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant (2016) 0.75
Epidemiology of mucopolysaccharidoses. Mol Genet Metab (2017) 0.75
Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases. Pediatr Blood Cancer (2016) 0.75
Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet (2019) 0.75
Common Variable Immunodeficiency Caused by FANC Mutations. J Clin Immunol (2017) 0.75
Allogeneic hematopoietic stem cell transplantation for Chediak-Higashi syndrome. Pediatr Transplant (2015) 0.75
Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transplant (2017) 0.75
Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. Pediatr Blood Cancer (2015) 0.75
Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia. Blood (2015) 0.75